In terms of optimal target selection, CS1 (CD319 or SLAMF7) is highly expressed on > 95% MM cells, and more commonly expressed on MM than BCMA [5], irrespective of genetic abnormalities and disease stage [6]. The gene discussed is SLAMF7; the disease is Miyoshi myopathy.